GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational Prospective

Table 3

GDF-15 patents related to diabetes, cardiovascular diseases, and chronic kidney diseases.

Patent	Applicant	Title
WO2011144571A2	F. Hoffmann-La Roche Ag	GDF-15 based means and methods for survival and recovery prediction in acute inflammation
WO2012138919A2	Amgen Inc.	Method of treating or ameliorating metabolic disorders using GDF-15
WO2012146645A1	F. Hoffmann-La Roche Ag	Diagnosis of kidney injury after surgery
EP2336784A1	Roche Diagnostics GmbH	GDF-15 and/or Troponin T for predicting kidney failure in heart surgery patients
EP2388594A1	Roche Diagnostics GmbH	GDF-15 based means and methods for survival and recovery prediction in acute inflammation
WO2009141357A1	Roche Diagnostics Gmbh, F. Hoffmann-La Roche Ag	GDF-15 as biomarker in type 1 diabetes
US 8,771,961 B2	Roche Diagnostics Operations, Inc.	Monitoring myocardial infarction and its treatment
EP1884777A1	Medizinische Hochschule Hannover	Means and methods for assessing the risk of cardiac interventions based on GDF-15
EP2439535A1	F. Hoffmann-La Roche AG	Diagnosis of diabetes related heart disease, GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus
WO2013113008A1	Amgen Inc.	GDF-15 polypeptides-ameliorating metabolic disorders
WO2010048670A1	St. Vincent’s Hospital Sydney Limited	Method of prognosis in chronic kidney disease
WO2011073382A1	Roche Diagnostics Gmbh	GDF-15 and/or troponin T for predicting kidney failure in heart surgery patients